David A. Santos's most recent trade in Rigel Pharmaceuticals was a trade of 19,430 Common Stock done . Disclosure was reported to the exchange on Feb. 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 19,430 | 62,870 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.62 per share. | 10 Feb 2026 | 3,546 | 43,440 (0%) | 0% | 34.6 | 122,763 | Common Stock |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.01 per share. | 02 Feb 2026 | 5,718 | 46,986 (0%) | 0% | 36.0 | 205,905 | Common Stock |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2025 | 7,394 | 7,394 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 7,850 | 7,850 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 6,875 | 6,875 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 20.92 per share. | 04 Feb 2025 | 2,125 | 53,500 (0%) | 0% | 20.9 | 44,457 | Common Stock |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 21.93 per share. | 04 Feb 2025 | 1,796 | 51,704 (0%) | 0% | 21.9 | 39,379 | Common Stock |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 19,717 | 55,625 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 14,788 | 14,788 | - | - | Employee Stock Option (Right to Buy) | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2024 | 8,000 | 8,000 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 80,000 | 80,000 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 78,500 | 78,500 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharma | A. David Santos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.14 per share. | 02 Feb 2024 | 8,918 | 349,093 (0%) | 0% | 1.1 | 10,167 | Common Stock |
| Rigel Pharma | A. Santos David | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.13 per share. | 02 Feb 2024 | 5,601 | 358,011 (0%) | 0% | 1.1 | 6,329 | Common Stock |
| Rigel Pharma | A. David Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 209,000 | 363,612 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharma | David Santos A. | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 157,000 | 157,000 | - | - | Employee Stock Option (Right to Buy) | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.66 per share. | 02 Feb 2023 | 5,388 | 144,612 (0%) | 0% | 1.7 | 8,945 | Common Stock |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 160,000 | 160,000 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 80,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 50,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharma | David A. Santos | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 50,000 | 60,000 (0%) | 0% | 0 | Common Stock |